All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @fatdadlosingweight on TikTok · 80s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @fatdadlosingweight's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:01Alright, this first video is gonna be me starting my first month on 2.4 milligrams of what go be.
  2. 0:10I think I'm just gonna shoot it up in the same spot I have been doing, which is two fingers
  3. 0:18from my belly button. So if you guys got any other ideas or options where to shoot up at,
  4. 0:26I know they say the stomach. You have more like side effects and stuff like that, but
  5. 0:32I think if I do have some side effects, I'm gonna do it at my thigh next, but we'll see how this
  6. 0:42how this week goes first. So give me a second. Alright, so I just tickled it off. So like I said
  7. 0:54about, I usually do two fingers away right there. Take your ear clicks on like that. That's about it.
  8. 1:16It should turn yellow. I guess.

@fatdadlosingweight's 100-pound Wegovy claim, fact-checked

FadDadLosingWeight

TikTok creator

22.7K viewsWatch on TikTok

Quick answer

The creator is self-injecting semaglutide 2.4 mg (Wegovy's approved maintenance dose) into the abdomen and attributing GI side effects to the injection site rather than the drug's mechanism. He is also describing a rapid injection technique that may not meet the six-second hold time Novo Nordisk specifies for full dose delivery. His 100-pound weight loss target over 12 months significantly exceeds average outcomes seen in the STEP trial program.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @fatdadlosingweight's 100-pound Wegovy claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@fatdadlosingweight's 100-pound Wegovy claim, fact-checked" from FadDadLosingWeight. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-injecting semaglutide 2.

The reason this review is not generic is the source wording and the canonical claim label "glp1 first month taken wegovy 2 4mg 300 to 200 in a year may." In this clip, the useful excerpt is: "Alright, this first video is gonna be me starting my first month on 2." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GI side effects like nausea affect roughly 44% of patients at the 2.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is self-injecting semaglutide 2.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-injecting semaglutide 2.4 mg (Wegovy's approved maintenance dose) into the abdomen and attributing GI side effects to the injection site rather than the drug's mechanism. He is also describing a rapid injection technique that may not meet the six-second hold time Novo Nordisk specifies for full dose delivery. His 100-pound weight loss target over 12 months significantly exceeds average outcomes seen in the STEP trial program.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of ~15% of body weight over 68 weeks at 2.4 mg semaglutide, not the ~33% this creator's goal implies.
  • GI side effects like nausea affect roughly 44% of patients at the 2.4 mg dose per STEP trial data, and are caused by the drug's mechanism, not the injection site chosen.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of ~15% of body weight over 68 weeks at 2.4 mg semaglutide, not the ~33% this creator's goal implies.
  • GI side effects like nausea affect roughly 44% of patients at the 2.4 mg dose per STEP trial data, and are caused by the drug's mechanism, not the injection site chosen.
  • Novo Nordisk's prescribing information specifies a six-second post-click hold for the Wegovy autoinjector. Skipping this step risks incomplete dose delivery.
  • Approved injection sites for Wegovy are abdomen, upper thigh, and upper arm. Rotating between them reduces lipohypertrophy risk, which can impair absorption over time.
  • The stomach-causes-more-side-effects belief is widespread in online GLP-1 communities but is not supported by pharmacokinetic or clinical trial data.
  • Blundell et al. (2022, Diabetes, Obesity and Metabolism) found modest absorption differences between injection sites for semaglutide, but no clinically meaningful difference in adverse event rates.
  • A 100-pound weight loss goal requires significant dietary and behavioral changes alongside semaglutide. The drug is not sufficient on its own to produce outcomes that far above trial averages.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @fatdadlosingweight actually say?

He's starting his first week at the 2.4 mg Wegovy maintenance dose, self-injecting into his abdomen "two fingers from my belly button." He mentions he's heard the stomach causes more side effects and floats switching to his thigh if problems come up. He also references the pen clicking and turning yellow as confirmation the dose delivered. That's the sum of the clinical content here.

To his credit, this isn't someone claiming Wegovy will cure anything. It's a guy documenting a lifestyle change for his kids, aiming to drop 100 pounds in a year. The injection technique walkthrough is where things get medically interesting, and where a few things need correcting.

Does the science back this up?

Partially. The approved injection sites for semaglutide are abdomen, upper arm, and thigh, so he's not wrong to consider all three. But the claim that the stomach causes "more side effects" is not well supported by the evidence.

The STEP 1 trial (Wilding et al., 2021, NEJM) and subsequent pharmacokinetic analyses did not identify injection site as a meaningful driver of GI side effects like nausea and vomiting. Those side effects are driven by the drug's mechanism, specifically GLP-1 receptor activation in the gut and brainstem, not by where the needle goes. A 2022 review in Diabetes, Obesity and Metabolism (Blundell et al.) confirmed that absorption rates differ modestly by site, with abdominal injection producing slightly faster absorption than thigh, but this does not translate to a clinically significant increase in nausea for most people. The stomach-equals-more-side-effects idea is a piece of patient-community folklore that has outrun the data.

What did they get wrong (or right)?

Let's give him credit first. Rotating injection sites is actually good practice. The FDA prescribing information for Wegovy recommends rotating sites to reduce lipohypertrophy risk, so his instinct to try the thigh isn't wrong, just based on a shaky reason.

What he got wrong: the idea that the abdomen is uniquely problematic for side effects. That belief is widespread on TikTok and Reddit GLP-1 communities, but it does not hold up clinically. If he switches to his thigh expecting fewer nausea episodes and they persist, which is likely during dose escalation, he may incorrectly conclude the thigh isn't working either.

The pen technique description, "it should turn yellow," is consistent with how Novo Nordisk's autoinjector confirms dose delivery. That part is accurate. However, he says he "tickled it off," which sounds like a very brief injection hold. Novo Nordisk recommends holding the pen against the skin for at least six seconds after the click to ensure full dose delivery. A rushed injection can result in partial dosing.

What should you actually know?

A few things worth knowing if you're starting or already on semaglutide. First, GI side effects during dose escalation, and 2.4 mg is the top maintenance dose, are common regardless of injection site. The STEP trials reported nausea in roughly 44 percent of patients at the highest dose. That's the drug working on your gut motility and appetite centers, not a problem with your technique.

Second, injection site rotation matters, but for skin health reasons, not side effect management. Rotating between abdomen, thigh, and upper arm prevents localized fat buildup that can actually impair absorption over time.

Third, the six-second hold after the click is not optional. Studies on autoinjector adherence have shown incomplete delivery is more common than patients realize when the hold step is skipped. If you're paying out of pocket for Wegovy, partial dosing is money wasted.

Finally, a 100-pound weight loss goal in 12 months is ambitious. The STEP 1 data showed average weight loss of around 15 percent of body weight over 68 weeks. At 300 pounds, 15 percent is 45 pounds. Hitting 100 pounds in 12 months would require outcomes well above the clinical trial average, and would likely require significant dietary and behavioral changes alongside the medication, which he seems aware of.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

FadDadLosingWeight · TikTok creator

22.7K views on this video

First month taken wegovy 2.4mg!! 300 to 200 in a year!! May 28 2025 to May 28 2026. Time to change my lifestyle around for these kids!!#fyp #wegovy #weightloss #fatdad #fattohealthy

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of ~15% of body weight over 68 weeks at 2.4 mg semaglutide, not the ~33% this creator's goal implies.

What does the video say about gi side effects like nausea affect roughly 44% of patients?

GI side effects like nausea affect roughly 44% of patients at the 2.4 mg dose per STEP trial data, and are caused by the drug's mechanism, not the injection site chosen.

What does the video say about novo nordisk's prescribing information specifies a six-second post-click hold for?

Novo Nordisk's prescribing information specifies a six-second post-click hold for the Wegovy autoinjector. Skipping this step risks incomplete dose delivery.

What does the video say about approved injection sites for wegovy?

Approved injection sites for Wegovy are abdomen, upper thigh, and upper arm. Rotating between them reduces lipohypertrophy risk, which can impair absorption over time.

What does the video say about the stomach-causes-more-side-effects belief?

The stomach-causes-more-side-effects belief is widespread in online GLP-1 communities but is not supported by pharmacokinetic or clinical trial data.

What does the video say about blundell et al. (2022, diabetes, obesity?

Blundell et al. (2022, Diabetes, Obesity and Metabolism) found modest absorption differences between injection sites for semaglutide, but no clinically meaningful difference in adverse event rates.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by FadDadLosingWeight, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.